They are in a tough situation all around: money-wise and in staying on the good side of regulators, That's inescapable and I thought they did a very good job of not sugar coating it in the call while still staying positive for the future.

With regulators, it's the holds and the investigations.

With money, as Antonio said in the call, they will be working from "a judicious budget, with focused spending". There have been too many irons in the fire, overextending the company. That simply can't continue. But also, as Antonio said, they are looking for value creation through partnerships "with minimal investment from the company" to get back some of the ability to trial multiple indications.

It seems like there will have to be some erosion of current potential shareholder value, whether it's from percentages given for cash generated by licensing deals or more dilution but potential is still there, though likely not in the triple digits, but potential nonetheless.